Recs

4

Is Abbott Labs the Right Stock to Retire With?

Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap. Let's figure out what makes a great retirement-oriented stock, then examine whether Abbott Labs (NYSE: ABT  ) has what we're looking for.

The right stocks for retirees
With decades to go before you need to tap your investments, you can take greater risks, weighing the chance of big losses against the potential for mind-blowing returns. But as retirement approaches, you no longer have the luxury of waiting out a downturn.

Sure, you still want good returns, but you also need to manage your risk and protect yourself against bear markets, which can maul your finances at the worst possible time. The right stocks combine both of these elements in a single investment.

When scrutinizing a stock, retirees should look for:

  • Size. Most retirees would rather not take a flyer on unproven businesses. Bigger companies may lack their smaller counterparts' growth potential, but they do offer greater security.
  • Consistency. While many investors look for fast-growing companies, conservative investors want to see steady, consistent gains in revenue, free cash flow, and other key metrics. Slow growth won't make headlines, but it will help prevent the kind of ugly surprises that suddenly torpedo a stock's share price.
  • Stock stability. Conservative retirement investors prefer investments that move less dramatically than typical stocks, and they particularly want to avoid big losses. These investments will give up some gains during bull markets, but they won't fall as far or as fast during bear markets. Beta measures volatility, but we also want a track record of solid performance as well.
  • Valuation. No one can afford to pay too much for a stock, even if its prospects are good. Using normalized earnings multiples helps smooth out one-time effects, giving you a longer-term context.
  • Dividends. Most of all, retirees look for stocks that can provide income through dividends. Retirees want healthy payouts now and consistent dividend growth over time -- as long as it doesn't jeopardize the company's financial health.

With those factors in mind, let's take a closer look at Abbott Labs.

Factor

What We Want to See

Actual

Pass or Fail?

Size Market cap > $10 billion $75.1 billion Pass
Consistency Revenue growth > 0% in at least four of five past years 5 years Pass
  Free cash flow growth > 0% in at least four of past five years 4 years Pass
Stock stability Beta < 0.9 0.29 Pass
  Worst loss in past five years no greater than 20% (8.3%) Pass
Valuation Normalized P/E < 18 18.28 Fail
Dividends Current yield > 2% 3.9% Pass
  5-year dividend growth > 10% 9.9% Fail
  Streak of dividend increases >= 10 years 39 years Pass
  Payout ratio < 75% 57.7% Pass
       
  Total score   8 out of 10

Source: Capital IQ, a division of Standard and Poor's. Total score = number of passes.

Abbott puts in a stellar performance on our 10-point scale, collecting eight points and missing only by the smallest of margins on the other two. The drugmaker faces many of the same challenges as its peers, but so far, Abbott has been up to the task.

As the measures above show, Abbott has been among the top stocks as far as consistent, stable returns. With only minimal losses during 2008's market meltdown, the company compares favorably to Merck (NYSE: MRK  ) and Eli Lilly (NYSE: LLY  ) , which saw much larger drops three years ago.

Recently, Abbott has seen respectable growth, especially from top-selling drugs like Humira, which treats conditions including rheumatoid arthritis and Crohn's disease. But just as Pfizer (NYSE: PFE  ) relies heavily on Lipitor, whose patents will soon expire , Abbott's lack of a strong pipeline raises the question of whether the company can continue to grow at roughly a 10% annual pace.

Perhaps the best thing going for Abbott is its relative obscurity. It's much less of a household name than Pfizer or Johnson & Johnson (NYSE: JNJ  ) , based on interest from our new watchlist service. Abbott's no unknown by any means, but staying out of the full glare of the spotlight while giving good results year in and year out is exactly what conservative investors like retirees like to see from the solid and stable stocks in their portfolios.

Keep searching
Finding exactly the right stock to retire with is a tough task, but it's not impossible. Searching for the best candidates will help improve your investing skills, and teach you how to separate the right stocks from the risky ones.

Add Abbott Labs to My Watchlist, which will aggregate our Foolish analysis on it and all your other stocks.

If you want to retire rich, you need to be confident that you've got the basics of your investment strategy down pat. See if you're on track by following the 13 Steps to Investing Foolishly.

Fool contributor Dan Caplinger doesn't own shares of the companies mentioned in this article. Johnson & Johnson and Pfizer are Motley Fool Inside Value recommendations. Motley Fool Options has recommended a diagonal call position on Johnson & Johnson, which is also a Motley Fool Income Investor pick. The Fool and Motley Fool Alpha own shares of Abbott Laboratories and Johnson & Johnson. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1454481, ~/Articles/ArticleHandler.aspx, 12/22/2014 12:22:29 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger
TMFGalagan

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on Fool.com. With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated Moments ago Sponsored by:
DOW 17,890.05 85.25 0.48%
S&P 500 2,071.73 1.08 0.05%
NASD 4,765.45 0.07 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

12/22/2014 12:06 PM
ABT $46.31 Up +0.26 +0.56%
Abbott Laboratorie… CAPS Rating: *****
JNJ $106.36 Up +0.81 +0.77%
Johnson & Johnson CAPS Rating: *****
LLY $70.85 Down -1.56 -2.15%
Eli Lilly & Co. CAPS Rating: ****
MRK $58.59 Down -0.99 -1.67%
Merck & Co., Inc. CAPS Rating: ****
PFE $31.93 Down -0.02 -0.05%
Pfizer CAPS Rating: ****

Advertisement